About us

For InnoCore, the development of cutting edge technologies has high priority. This way, we aim to create next generation drug delivery products that will allow our customers to achieve and maintain a competitive market position. Innovation is considered essential. Next to continuously performing in-house R&D we actively exploit partnering and collaboration opportunities to complement our expertise and boost the innovation process. InnoCore has, for instance, established strategic collaborations in the areas of monodisperse controlled release microspheres and next generation drug eluting vascular stents that prevent late-stage thrombosis.

Furthermore, InnoCore is one of the Founding Fathers of the BioMedical Materials Program (BMM), a public private partnership in The Netherlands that focuses on research and development in the field of biomedical materials and drug delivery. InnoCore is actively participating in two BMM projects, Nextream (next generation vascular stents) and OAControl (new therapies for osteoarthritis) with a total budget of EURO 13 million.